Crossref
How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?
Hematology in Clinical Practice · 2023
DOI: 10.5603/hcp.2023.0002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2023. Verfasst von Aleksander Salomon-Perzyński und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Salomon-Perzyński, A., & Budziszewska, B. K. (2023). How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2023.0002
Vancouver
Salomon-Perzyński A, Budziszewska BK. How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?. Hematology in Clinical Practice. 2023. doi:10.5603/hcp.2023.0002
BibTeX
@article{SalomonPerzyski2023,
author = {Salomon-Perzyński, Aleksander and Budziszewska, Bożena Katarzyna},
title = {How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?},
journal = {Hematology in Clinical Practice},
year = {2023},
doi = {10.5603/hcp.2023.0002}
}
EUVIMED